Permanent URL to this publication: http://dx.doi.org/10.5167/uzh-56746
Regan, M M; Price, K N; Giobbie-Hurder, A; Thürlimann, B; Gelber, R D (2011). Interpreting Breast International Group (BIG) 1-98: a randomized, double-blind, phase III trial comparing letrozole and tamoxifen as adjuvant endocrine therapy for postmenopausal women with hormone receptor-positive, early breast cancer. Breast Cancer Research, 13(3):209.
The Breast International Group (BIG) 1-98 study is a four-arm trial comparing 5 years of monotherapy with tamoxifen or with letrozole or with sequences of 2 years of one followed by 3 years of the other for postmenopausal women with endocrine-responsive early invasive breast cancer. From 1998 to 2003, BIG -98 enrolled 8,010 women. The enhanced design f the trial enabled two complementary analyses of efficacy and safety. Collection of tumor specimens further enabled treatment comparisons based on tumor biology. Reports of BIG 1-98 should be interpreted in relation to each individual patient as she weighs the costs and benefits of available treatments. Clinicaltrials.gov ID: NCT00004205.
|Contributors:||Varga, Z, Caduff, R [et al.]|
|Item Type:||Journal Article, refereed, original work|
|Communities & Collections:||04 Faculty of Medicine > University Hospital Zurich > Institute of Surgical Pathology|
04 Faculty of Medicine > University Hospital Zurich > Clinic for Gynecology
|DDC:||610 Medicine & health|
|Deposited On:||24 Jan 2012 15:13|
|Last Modified:||29 Nov 2013 08:56|
|Citations:||Web of Science®. Times Cited: 8|
Scopus®. Citation Count: 10
Users (please log in): suggest update or correction for this item
Repository Staff Only: item control page